Nasus Pharma (NSRX) Debt to Equity (2024)
Nasus Pharma (NSRX) reported Debt to Equity of -$0.56 for Q4 2024.
Nasus Pharma (NSRX) Debt to Equity (2024) Analysis & Trends
Nasus Pharma has reported Debt to Equity for 1 years, with the latest figure at -$0.56 in Q4 2024.
- For the quarter ending Q4 2024, Debt to Equity changed N/A year-over-year to -$0.56; the trailing twelve-month figure through Dec 2024 stood at -$0.56 (changed N/A YoY), and the FY2024 full-year result was -$0.56, changed N/A from the prior year.
- Debt to Equity for Q4 2024 stood at -$0.56.
- The five-year high for Debt to Equity was -$0.56 in Q4 2024, with the low at -$0.56 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 1.39 |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 0.68 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -9.70 |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 1.07 |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 6.24 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 0.94 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.72 |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.22 |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -0.56 |